123 related articles for article (PubMed ID: 22465921)
1. [Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Ono T
Yakugaku Zasshi; 2012; 132(4):449-53. PubMed ID: 22465921
[TBL] [Abstract][Full Text] [Related]
2. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Sumi A; Yamanaka-Hanada N; Bai F; Makino T; Mizukami H; Ono T
Biol Pharm Bull; 2011; 34(6):824-30. PubMed ID: 21628879
[TBL] [Abstract][Full Text] [Related]
3. Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis.
Nomura K; Liu N; Nagai K; Hasegawa T; Kobayashi I; Nogaki F; Tanaka M; Arai H; Fukatsu A; Kita T; Ono T
Lab Invest; 2007 Feb; 87(2):150-60. PubMed ID: 17179958
[TBL] [Abstract][Full Text] [Related]
4. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
Tanaka M; Arai H; Liu N; Nogaki F; Nomura K; Kasuno K; Oida E; Kita T; Ono T
Kidney Int; 2005 Jun; 67(6):2123-33. PubMed ID: 15882255
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide-triggered acute aggravation of mesangioproliferative glomerulonephritis through activation of coagulation in a high IgA strain of ddY mice.
Shimosawa M; Sakamoto K; Tomari Y; Kamikado K; Otsuka H; Liu N; Kitamura H; Uemura K; Nogaki F; Mori N; Muso E; Yoshida H; Ono T
Nephron Exp Nephrol; 2009; 112(4):e81-91. PubMed ID: 19546589
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor and factor v involvement in rat peritoneal fibrosis.
Saito H; Kitamoto M; Kato K; Liu N; Kitamura H; Uemura K; Nogaki F; Takeda T; Mori N; Ono T
Perit Dial Int; 2009; 29(3):340-51. PubMed ID: 19458308
[TBL] [Abstract][Full Text] [Related]
7. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
[TBL] [Abstract][Full Text] [Related]
8. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
9. Coagulation factor Xa modulates airway remodeling in a murine model of asthma.
Shinagawa K; Martin JA; Ploplis VA; Castellino FJ
Am J Respir Crit Care Med; 2007 Jan; 175(2):136-43. PubMed ID: 17082493
[TBL] [Abstract][Full Text] [Related]
10. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
12. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Becker RC; Alexander J; Dyke CK; Harrington RA
Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
[TBL] [Abstract][Full Text] [Related]
13. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
14. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease.
Borensztajn K; Peppelenbosch MP; Spek CA
Trends Mol Med; 2008 Oct; 14(10):429-40. PubMed ID: 18774340
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
Alexander JH; Singh KP
Am J Cardiovasc Drugs; 2005; 5(5):279-90. PubMed ID: 16156684
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease-Activated Receptor Pathway.
Ichikawa H; Shimada M; Narita M; Narita I; Kimura Y; Tanaka M; Osanai T; Okumura K; Tomita H
J Am Heart Assoc; 2019 Apr; 8(8):e012195. PubMed ID: 30957622
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice.
Hayashi S; Oe Y; Fushima T; Sato E; Sato H; Ito S; Takahashi N
Biochem Biophys Res Commun; 2017 Jan; 483(1):547-552. PubMed ID: 28025140
[TBL] [Abstract][Full Text] [Related]
18. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
19. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.
Morris DR; Ding Y; Ricks TK; Gullapalli A; Wolfe BL; Trejo J
Cancer Res; 2006 Jan; 66(1):307-14. PubMed ID: 16397244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
